Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Tomizawa M
A phase I/II clinical trial evaluating abiraterone in advanced breast cancer patients is also underway
SAR407899 (3 μM) completely blocks thrombin-induced shrinkage of human umbilical vein endothelial cells (HUVECs) and stress fiber formation
making it a good drug candidate for cancer therapy
It acts as a selective
DY-131 - CAS# 95167-41-2 60200 Tomizawa MDY131, also known as GSK 9089, CAS No. 95167 41 2, is a novel selective agonist at estrogen related receptors ERR and ERR. DY131 could potentiate the ERRgamma induced growth inhibition in LNCaP ERRgamma and DU145 ERRgamma cells in a dose dependent manner. ERRgamma may perform an antiproliferative or tumor suppressing function in prostate cancer cells. ERRgamma could be a novel therapeutic target for prostate cancer treatment. Product information CAS
US$ 98.00
US$ 69.99
US$ 34.99
US$ 8055.00
US$ 8055.00